Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis
- PMID: 19201235
- DOI: 10.1016/j.ymgme.2008.12.019
Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis
Abstract
Left untreated, phenylketonuria biochemically results in high phenylalanine concentrations in blood and tissues, and clinically especially in severe mental retardation. Treatment consists of severe dietary restriction of phenylalanine with more or less normal intellectual outcome as result when started early enough. It is unclear whether treatment for life is necessary. A clear relationship between plasma phenylalanine concentrations and cerebral outcome exists, but the precise pathophysiological mechanism is not understood. In studies in mice with phenylketonuria, the cerebral protein synthesis rate is decreased when compared to controls. The aim of the present study was to determine the protein synthesis rate in relation to the plasma phenylalanine concentrations in-vivo in patients with phenylketonuria by positron emission tomography brain studies after an intravenous l-[1-(11)C]-tyrosine bolus. Results showed a significant negative relationship (R(2)=0.40, p<0.01) between plasma phenylalanine concentration and the cerebral protein synthesis rate in 19 patients with phenylketonuria. At increased plasma phenylalanine concentrations, i.e. above 600-800micromol/l, the cerebral protein synthesis rate is clearly decreased compared to lower phenylalanine concentrations. These data suggest that cerebral protein metabolism in untreated adults with phenylketonuria can be abnormal due to high plasma phenylalanine concentrations. Hence, we speculate that it is important to continue dietary treatment into adulthood, aiming at plasma phenylalanine concentrations <600-800micromol/l.
Similar articles
-
Long term studies of untreated phenylketonuria II: the plasma phenylalanine level.Neuropadiatrie. 1978 Aug;9(3):255-67. doi: 10.1055/s-0028-1091486. Neuropadiatrie. 1978. PMID: 581401
-
Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis.J Cereb Blood Flow Metab. 2015 Feb;35(2):200-5. doi: 10.1038/jcbfm.2014.183. Epub 2014 Oct 29. J Cereb Blood Flow Metab. 2015. PMID: 25352046 Free PMC article. Clinical Trial.
-
Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes.Mol Genet Metab. 2013 Dec;110(4):418-23. doi: 10.1016/j.ymgme.2013.09.001. Epub 2013 Sep 9. Mol Genet Metab. 2013. PMID: 24090706 Review.
-
Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.Pediatrics. 1993 Oct;92(4):570-3. Pediatrics. 1993. PMID: 8414829
-
Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?J Inherit Metab Dis. 2009 Feb;32(1):46-51. doi: 10.1007/s10545-008-0946-2. Epub 2009 Jan 13. J Inherit Metab Dis. 2009. PMID: 19191004 Review.
Cited by
-
Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice.J Inherit Metab Dis. 2018 Jul;41(4):709-718. doi: 10.1007/s10545-018-0150-y. Epub 2018 Mar 8. J Inherit Metab Dis. 2018. PMID: 29520738 Free PMC article.
-
High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).Mol Genet Metab. 2016 Jan;117(1):5-11. doi: 10.1016/j.ymgme.2015.11.012. Epub 2015 Nov 26. Mol Genet Metab. 2016. PMID: 26653793 Free PMC article.
-
Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.Dev Neuropsychol. 2016 May-Jun;41(4):245-260. doi: 10.1080/87565641.2016.1243109. Epub 2016 Nov 2. Dev Neuropsychol. 2016. PMID: 27805419 Free PMC article.
-
Phenylketonuria.Nat Rev Dis Primers. 2021 May 20;7(1):36. doi: 10.1038/s41572-021-00267-0. Nat Rev Dis Primers. 2021. PMID: 34017006 Free PMC article. Review.
-
Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments.Front Psychiatry. 2019 Sep 10;10:561. doi: 10.3389/fpsyt.2019.00561. eCollection 2019. Front Psychiatry. 2019. PMID: 31551819 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical